# Protagenic Therapeutics, Inc.\\new: overview PTIX · OTC · CIK 1022899 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31 Pages: [Overview](/companies/ptix.md) · [Financials](/companies/ptix/financials.md) · [Filings](/companies/ptix/filings.md) · [Insiders](/companies/ptix/insiders.md) Latest reported revenue: [$0](/filings/0001493152-26-038255.md) for Q4 FY2026, three months to 2026-03-31, from the 10-K filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001493152-26-038255). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | [0.0](/filings/0001493152-24-045913.md) | [0.0 d](/filings/0001641172-25-001600.md) | [0.0](/filings/0001641172-25-009923.md) | [0.0](/filings/0001641172-25-027041.md) | [0.0 d](/filings/0001493152-25-025201.md) | [0.0 d](/filings/0001493152-26-009301.md) | [0.0 d](/filings/0001493152-26-038255.md) | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.11)](/filings/0001493152-25-025201.md) | [(0.16)](/filings/0001493152-26-009301.md) | [(2.75)](/filings/0001641172-25-009923.md) | [(1.37)](/filings/0001493152-26-039221.md) | [(0.47)](/filings/0001493152-25-025201.md) | [1.14](/filings/0001493152-26-009301.md) | not reported | [(0.53)](/filings/0001493152-26-039221.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-03-31) | FY2026 (2026-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0](/filings/0001493152-24-019018.md) | [0.0](/filings/0001641172-25-001600.md) | [0.0](/filings/0001641172-25-001600.md) | [0.0](/filings/0001493152-26-038255.md) | [0.0](/filings/0001493152-26-038255.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.82)](/filings/0001493152-24-019018.md) | [(1.15)](/filings/0001641172-25-001600.md) | [(1.13)](/filings/0001641172-25-001600.md) | [(0.67)](/filings/0001493152-26-038255.md) | [0.59](/filings/0001493152-26-038255.md) | | Free cash flow | $k | [(1,996)](/filings/0001493152-24-019018.md) | [(3,854)](/filings/0001641172-25-001600.md) | not reported | not reported | [(2,810)](/filings/0001493152-26-038255.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ptix/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [DRW Securities, LLC](/funds/1481986.md) | 2026-06-30 | $16.4k | 41,783 | | Unchanged | | [FNY Investment Advisers, LLC](/funds/1742998.md) | 2026-06-30 | $9 | 25,000 | | Unchanged | ## Recent filings [All 490 filings](/companies/ptix/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-20 | 11:26 ET | [8-K](/filings/0001493152-26-039410.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-039410 | | 2026-08-19 | 16:28 ET | [10-Q](/filings/0001493152-26-039221.md) | Quarterly report, period 2026-06-30 | 0001493152-26-039221 | | 2026-08-14 | 15:19 ET | [10-K](/filings/0001493152-26-038255.md) | Annual report, period 2026-03-31 | 0001493152-26-038255 | | 2026-04-07 | 19:13 ET | [8-K](/filings/0001493152-26-015365.md) | 5.02 Departure or appointment of officers or directors | 0001493152-26-015365 | | 2026-03-09 | 07:46 ET | [10-Q](/filings/0001493152-26-009301.md) | Quarterly report, period 2025-12-31 | 0001493152-26-009301 | | 2026-03-03 | 21:27 ET | [8-K](/filings/0001493152-26-008605.md) | 5.02 Departure or appointment of officers or directors | 0001493152-26-008605 | | 2026-02-24 | 20:49 ET | [8-K](/filings/0001493152-26-007800.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-007800 | | 2026-01-05 | 07:45 ET | [8-K](/filings/0001493152-26-000263.md) | 3.01 Delisting notice | 0001493152-26-000263 | | 2025-12-05 | 16:52 ET | [DEF 14A](/filings/0001493152-25-026414.md) | Proxy statement, period 2025-12-05 | 0001493152-25-026414 | | 2025-11-26 | 17:26 ET | [10-Q](/filings/0001493152-25-025201.md) | Quarterly report, period 2025-09-30 | 0001493152-25-025201 | ## Latest annual report [Form 10-K for the fiscal year ended Mar 31, 2026](/filings/0001493152-26-038255.md), filed Aug 14, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1022899 - Tickers: PTIX - Exchange: OTC - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.